tiprankstipranks
Trending News
More News >
Clinuvel Pharmaceuticals Limited (AU:CUV)
ASX:CUV
Australian Market

Clinuvel Pharmaceuticals (CUV) Financial Statements

Compare
67 Followers

Clinuvel Pharmaceuticals Financial Overview

Clinuvel Pharmaceuticals 's market cap is currently $541.34M. The company's EPS TTM is AU$0.28; its P/E ratio is 13.95; and it has a dividend yield of 0.47%. Clinuvel Pharmaceuticals is scheduled to report earnings on February 26, 2025, and the estimated EPS forecast is AU$0.38. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Jun 23Jun 22Jun 21Jun 20
Income Statement
Total RevenueAU$ 88.18MAU$ 78.32MAU$ 65.72MAU$ 47.98MAU$ 32.57M
Gross ProfitAU$ 80.45MAU$ 50.59MAU$ 46.62MAU$ 35.20MAU$ 18.43M
Operating IncomeAU$ 48.01MAU$ 40.91MAU$ 33.08MAU$ 26.70MAU$ 10.20M
EBITDAAU$ 51.86MAU$ 46.37MAU$ 35.08MAU$ 26.57MAU$ 11.99M
Net IncomeAU$ 35.64MAU$ 30.60MAU$ 20.88MAU$ 24.73MAU$ 16.65M
Balance Sheet
Cash & Short-Term InvestmentsAU$ 183.87MAU$ 156.81MAU$ 121.51MAU$ 82.69MAU$ 66.75M
Total AssetsAU$ 231.12MAU$ 194.52MAU$ 144.81MAU$ 108.57MAU$ 81.54M
Total DebtAU$ 879.78KAU$ 999.87KAU$ 1.26MAU$ 1.30MAU$ 1.32M
Net DebtAU$ -182.99MAU$ -22.87MAU$ -26.15MAU$ -35.84MAU$ -24.33M
Total LiabilitiesAU$ 28.11MAU$ 29.89MAU$ 19.25MAU$ 9.83MAU$ 9.48M
Stockholders' EquityAU$ 203.01MAU$ 164.63MAU$ 125.56MAU$ 98.74MAU$ 72.07M
Cash Flow
Free Cash FlowAU$ 31.48MAU$ 35.88MAU$ 39.44MAU$ 18.41MAU$ 13.30M
Operating Cash FlowAU$ 37.05MAU$ 36.91MAU$ 39.87MAU$ 19.26MAU$ 14.19M
Investing Cash FlowAU$ -29.03MAU$ -1.03MAU$ -434.44KAU$ -854.33KAU$ -888.83K
Financing Cash FlowAU$ -3.57MAU$ -2.24MAU$ -1.50MAU$ -1.48MAU$ -1.49M
Currency in AUD

Clinuvel Pharmaceuticals Earnings and Revenue History

Clinuvel Pharmaceuticals Debt to Assets

Clinuvel Pharmaceuticals Cash Flow

Clinuvel Pharmaceuticals Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis